Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24865954 | 0.90 | KMT2A (0.42) | KMT2ASMN1; SMN2EPHX1HRH3CHRM4 | |
| SCHEMBL20227961 | 0.88 | — | — | |
| SCHEMBL24199393 | 0.84 | MAPT (0.32) | OPRM1OPRL1 | |
| SCHEMBL22302354 | 0.83 | NCF1 (0.39) | — | |
| SCHEMBL12563470 | 0.82 | SMN1; SMN2 (0.34) | SMN1; SMN2EPHX1HRH3 | |
| SCHEMBL102034 | 0.82 | SMN1; SMN2 (0.41) | SMN1; SMN2EPHX1HRH3EPHX2 | |
| SCHEMBL25089943 | 0.81 | HRH3 (0.35) | HRH3 | |
| SCHEMBL11919253 | 0.77 | KMT2A (0.41) | KMT2ASMN1; SMN2EPHX1OPRM1OPRL1 | |
| SCHEMBL18270420 | 0.76 | OPRK1 (0.30) | — | |
| SCHEMBL25856202 | 0.75 | ACHE (0.47) | KMT2ASMN1; SMN2EPHX1HRH3OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067642-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-02-29 | — | — | US | disclosed |
| US-20230331722-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230066136-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230066136-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | KMT2A 682/4885SMN1; SMN2 368/4885EPHX1 1508/4885 |
| US-20230331722-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | KMT2A 682/4885SMN1; SMN2 368/4885EPHX1 1508/4885 |
| US-20240067642-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | KMT2A 682/4885SMN1; SMN2 368/4885EPHX1 1508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.